Ⅳ期維吾爾族非小細胞肺癌組織EML4-ALK表達與臨床病理特征的關系
發(fā)布時間：2018-07-31 08:14
【摘要】：目的肺癌是目前發(fā)病率較高的腫瘤,是癌癥相關死亡重要的原因之一。NCCN指南已將克唑替尼(Crizotinib)作為EML4-ALK融合基因患者的標準一線治療。本研究探討維吾爾族Ⅳ期非小細胞肺癌(non-small cell lung cancer,NSCLC)患者的EML4-ALK重排與臨床病理特征之間的關系。方法回顧性分析2015-01-01-2016-05-31,在新疆醫(yī)科大學附屬腫瘤醫(yī)院采用Ventana全自動免疫組化法進行EML4-ALK檢測的158例維吾爾族Ⅳ期NSCLC患者的臨床資料,分析其臨床病理特征與EML4-ALK重排的關系。結(jié)果 158例維爾族Ⅳ期NSCLC患者中,檢測到EML4-ALK融合基因11例(6.96%)。未檢測到EML4-ALK融合基因的患者147例(93.04%)。EML4-ALK突變與吸煙史、患者的表皮生長因子受體(epidermal growth factor receptor,EGFR)突變狀況、病理類型有關,P0.05;而與性別、年齡、有無淋巴結(jié)轉(zhuǎn)移及分化程度無關,P0.05。無EGFR突變的不吸煙的腺癌患者EML4-ALK融合基因陽性率高。結(jié)論EML4-ALK融合基因多表達于腺癌、不吸煙或既往有吸煙史,且同時無EGFR突變的維吾爾族Ⅳ期NSCLC患者。明確Ⅳ期維吾爾族NSCLC患者中EML4-ALK的表達與臨床病理學特征之間的聯(lián)系,便于更好地發(fā)現(xiàn)相應的治療優(yōu)勢人群,進行及時的檢測與治療。
[Abstract]:Objective lung cancer is a high incidence of tumor and is one of the important causes of cancer related death. The.NCCN guide has used Crizotinib as the standard first-line treatment for patients with EML4-ALK fusion gene. This study explores the EML4-ALK rearrangement and presence of non-small cell lung cancer (NSCLC) in Uygur stage IV non small cell lung cancer (NSCLC). The relationship between the pathological features of the bed. Methods a retrospective analysis of the clinical data of 158 Uygur IV NSCLC patients in the Affiliated Tumor Hospital of Xinjiang Medical University, which was detected by Ventana automatic immunohistochemical method by EML4-ALK, was analyzed. The relationship between the clinicopathological features and the EML4-ALK rearrangement was analyzed. Results 158 cases were vill. Of the NSCLC patients with stage IV NSCLC, EML4-ALK fusion gene was detected in 11 cases (6.96%). 147 cases (93.04%) of.EML4-ALK mutation and smoking history were not detected in patients with EML4-ALK fusion gene, the mutation of epidermal growth factor receptor (epidermal growth factor receptor, EGFR), pathological type, P0.05, and lymph node transition with sex and age. It was not related to the degree of migration and differentiation, and the positive rate of EML4-ALK fusion gene was higher in non smoking non smoking adenocarcinoma patients with P0.05. without EGFR mutation. Conclusion EML4-ALK fusion gene is more expressed in adenocarcinoma, no smoking or smoking history, and there is no EGFR mutation in Uygur IV NSCLC patients. The expression and clinical manifestation of EML4-ALK in Uygur NSCLC patients are clearly defined and clinical. The connection between pathological characteristics is conducive to better finding the corresponding treatment of the dominant population, and timely detection and treatment.
【作者單位】： 新疆醫(yī)科大學附屬腫瘤醫(yī)院肺內(nèi)科;
【基金】：烏魯木齊市科技局一般項目(Y161310008) 新疆醫(yī)科大學創(chuàng)新基金(XJDCX201548)
【分類號】：R734.2
本文編號：2154974
[Abstract]:Objective lung cancer is a high incidence of tumor and is one of the important causes of cancer related death. The.NCCN guide has used Crizotinib as the standard first-line treatment for patients with EML4-ALK fusion gene. This study explores the EML4-ALK rearrangement and presence of non-small cell lung cancer (NSCLC) in Uygur stage IV non small cell lung cancer (NSCLC). The relationship between the pathological features of the bed. Methods a retrospective analysis of the clinical data of 158 Uygur IV NSCLC patients in the Affiliated Tumor Hospital of Xinjiang Medical University, which was detected by Ventana automatic immunohistochemical method by EML4-ALK, was analyzed. The relationship between the clinicopathological features and the EML4-ALK rearrangement was analyzed. Results 158 cases were vill. Of the NSCLC patients with stage IV NSCLC, EML4-ALK fusion gene was detected in 11 cases (6.96%). 147 cases (93.04%) of.EML4-ALK mutation and smoking history were not detected in patients with EML4-ALK fusion gene, the mutation of epidermal growth factor receptor (epidermal growth factor receptor, EGFR), pathological type, P0.05, and lymph node transition with sex and age. It was not related to the degree of migration and differentiation, and the positive rate of EML4-ALK fusion gene was higher in non smoking non smoking adenocarcinoma patients with P0.05. without EGFR mutation. Conclusion EML4-ALK fusion gene is more expressed in adenocarcinoma, no smoking or smoking history, and there is no EGFR mutation in Uygur IV NSCLC patients. The expression and clinical manifestation of EML4-ALK in Uygur NSCLC patients are clearly defined and clinical. The connection between pathological characteristics is conducive to better finding the corresponding treatment of the dominant population, and timely detection and treatment.
【作者單位】： 新疆醫(yī)科大學附屬腫瘤醫(yī)院肺內(nèi)科;
【基金】：烏魯木齊市科技局一般項目(Y161310008) 新疆醫(yī)科大學創(chuàng)新基金(XJDCX201548)
【分類號】：R734.2
【相似文獻】
相關期刊論文 前1條
1 周清;;肺癌中EML4-ALK突變導致對ALK抑制劑耐藥的研究[J];循證醫(yī)學;2010年06期
，本文編號：2154974
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2154974.html
最近更新
教材專著
